Clinical trials: Cancer Refractory
Lymphoma
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Primary Objective: To evaluate the efficacy of SAR245409 as determined by the objective response rate (ORR) in patients with 1 of following relapsed or refractory lymphoma or leukemia subtypes: mantle cell lymphoma (MCL)…
- Trial name
- NCT01403636
- Testing
- SAR245409
- Where
- 30 sites in United States, Australia and 4 more
- Volunteers
- 167 people
- Sponsor
- Sanofi
Follicular Lymphoma, Marginal Zone Lymphoma
A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
The goal of this study is to assess whether axicabtagene ciloleucel improves the clinical outcome in participants with relapsed or refractory indolent non-Hodgkin lymphoma (r/r) iNHL.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma
- Trial name
- ZUMA-5 (NCT03105336)
- Testing
- Axicabtagene ciloleucel, Cyclophosphamide, Fludarabine
- Where
- 19 sites in United States, France
- Volunteers
- 159 people
- Sponsor
- Kite, A Gilead Company
Esophageal Squamous Cell Carcinoma
Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
This study will test a new potential treatment for advanced esophageal squamous cell cancer (ESCC) for patients whose initial treatment has stopped working.
- Trial name
- NCT07403136
- Testing
- Vebrekotuzumab, PD-1 antibody
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Relapsed/Refractory Acute Myeloid Leukemia
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in relapsed/refractory acute myeloid leukemia subjects.
- Trial name
- NCT05518357
- Testing
- LILRB4 STAR-T
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
Leukemia, Myelodysplastic Syndromes
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar trihydrochloride, a modulator of multidrug resistance (MDR), may help daunorubicin and cytarabine…
- Trial name
- NCT00046930
- Testing
- filgrastim, sargramostim, cytarabine
- Where
- 92 sites in United States, Israel
- Volunteers
- 449 people
- Sponsor
- Eastern Cooperative Oncology Group
Differentiated Thyroid Cancer, Gender
Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
Lenvatinib is approved for the treatment of radioiodine refractory differentiated thyroid cancer. Despite gender can play a crucial role un in safety and efficacy of oncological product, little is know on gender difference in…
- Trial name
- Gisel (NCT05789667)
- Testing
- Lenvatinib
- Where
- Italy
- Volunteers
- 138 people
- Sponsor
- Regina Elena Cancer Institute
Lymphoma, Non-Hodgkin
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
- Trial name
- TRANSCENDWORLD (NCT03484702)
- Testing
- JCAR017
- Where
- 20 sites in Austria, Belgium and 9 more
- Volunteers
- 113 people
- Sponsor
- Celgene
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Multiple Myeloma
Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this Phase 1 study is to characterize the pharmacokinetic (PK) and tolerability of oral ixazomib (MLN9708) when administered in combination with lenalidomide and dexamethasone in adult Asian participants with…
- Trial name
- NCT01645930
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 5 sites in Hong Kong, Singapore and 1 more
- Volunteers
- 43 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer
The primary objective of this study is to evaluate the objective response rate (ORR = CR + PR) of pitavastatin combined with chemotherapy, guided by PTC (patient-derived tumor-like cell cluster) drug sensitivity, in patients…
- Trial name
- CPPGPTCLC (NCT07351565)
- Testing
- Pitavastatin 1 mg daily or 4 mg daily
- Volunteers
- 22 people
- Sponsor
- Chang Chen
Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
This phase Ib trial studies the side effects and best dose of IRX-2 when given together with cyclophosphamide and nivolumab in treating patients with liver cancer that has come back or spread to other parts of the body and does…
- Conditions
- Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT03655002
- Testing
- Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Myeloid Malignancy, Acute Myeloid Leukemia
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
This is a Phase I dose finding study of GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKE®) for the treatment of select CD33-expressing refractory/relapsed myeloid malignancies in adults ≥ 18 years of age…
- Conditions
- Myeloid Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT06594445
- Testing
- GTB-360
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
This phase II trial tests the effect of total marrow and lymphoid irradiation (TMLI) in combination with fludarabine and melphalan as conditioning regimen in older patients with acute myeloid leukemia or high-risk myelodysplastic…
- Conditions
- Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT07582172
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Cancer, Neoplasms
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
This is an open-label, multicenter, 2-part study to determine the recommended Phase 2 dose (RP2D) for GSK2816126 given twice weekly by intravenous (IV) infusion.
- Trial name
- NCT02082977
- Testing
- GSK2816126
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Leukemia, Lymphoma
Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00012207
- Testing
- aldesleukin, therapeutic autologous lymphocytes, cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
- Trial name
- DURGA-3 (NCT06235229)
- Testing
- GC012F
- Where
- 10 sites in China
- Volunteers
- 110 people
- Sponsor
- Gracell Biotechnologies (Shanghai) Co., Ltd.
Ovarian Cancer
MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer
The purpose of this study is to evaluate the activity and the toxicity of capecitabine as monotherapy in the treatment of platinum resistant or refractory ovarian cancer.
- Trial name
- NCT00403429
- Testing
- capecitabine
- Where
- 17 sites in Italy
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute, Naples
Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
This phase II trial studies how well sirolimus, cyclosporine and mycophenolate mofetil works in preventing graft-vs-host disease (GVHD) in patients with blood cancer undergoing donor peripheral blood stem cell (PBSC) transplant.
- Conditions
- Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, Adult Myelodysplastic Syndrome
- Trial name
- NCT01251575
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 5 sites in United States, Denmark
- Volunteers
- 77 people
- Sponsor
- Fred Hutchinson Cancer Center
Solid Tumor, Advanced Solid Tumor
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Parts 1 and 2 The primary purpose of this study is to understand the safety of NL-201 when given intravenously as monotherapy in patients with advanced cancer to evaluate tolerability and to identify a recommended dose and…
- Trial name
- NCT04659629
- Testing
- NL-201, Pembrolizumab Injection [Keytruda]
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 59 people
- Sponsor
- Neurogene Inc.
B Cell Lymphoma, Multiple Myeloma
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
A single arm, open-label pilot study is designed to determine the safety and efficacy of CD19 and B-cell maturation antigen (BCMA) targeted allogenic CAR-T cells (RN1101) in patients with relapsed/refractory B-cell or plasma…
- Trial name
- NCT06976437
- Testing
- RN1101 injection
- Where
- China
- Volunteers
- 21 people
- Sponsor
- YANRU WANG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.